^
    Back
    Association details:
    Biomarker:Chr del(17p)
    Cancer:Small Lymphocytic Lymphoma
    Drug:Gazyva (obinutuzumab) (CD20 inhibitor) +
    Calquence (acalabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    CLL/SLL with del(17p)/TP53 mutation: First-line therapy...Preferred regimens…Acalabrutinib ± obinutuzumab